Supernus Pharmaceuticals SUPN (Amortization) accretion on investments

(Amortization) accretion on investments at other companies

Oruka Therapeutics, Inc.ORKA

$446K-75.2%

Jackson FinancialJXN

$14M+75.0%

PegasystemsPEGA

$321K-79.0%

BancFirst CorporationBANF

$427K+676%

HTF

Heartflow, Inc. Common StockHTFL

$836K+99.5%

Brighthouse FinancialBHF

$80M-3.0%

Other financials

Income statement

See full

Revenue$207.7M+38.6%

Gross profit$184.3M+37.5%

Operating income-$8.3M+18.8%

Net income-$2.3M+80.6%

EPS (diluted)-$0.04+81.0%

Balance sheet

See full

Cash & equivalents$186.3M+60.8%

Total debt$40.9M+26.6%

Total equity$1.1B+4.5%

Total assets$1.5B+11.4%

Cash flow

See full

Operating cash flow$66.5M+117%

CapEx--100%

Free cash flow$66.5M+120%

Valuation

See full

Market cap$2.62B+62.8%

Profitability

See full

Gross margin89.4%+1.0pp

Operating margin-7.8%-18.9pp

Net margin-3.7%-13.0pp

FCF margin27.9%+3.4pp

Returns & leverage

See full

Return on equity-2.8%-9.1pp

Debt / equity0×0.0×

Current ratio2×-0.5×

Where this comes from

Reported directly by Supernus Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium.

The official record: Supernus Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Supernus Pharmaceuticals's (amortization) accretion on investments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Supernus Pharmaceuticals's (amortization) accretion on investments?: Supernus Pharmaceuticals (SUPN) reported (amortization) accretion on investments of $192K in Q1 2026.